Sign in
Taking people in United StatesNo phase

Studies insulin control of fat breakdown before and after weight loss surgery

Studies people with severe obesity before and after gastric sleeve surgery.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis
Status
Recruiting
People taking part
30 people, planned
Started
1 Aug 2019
Expected to end
May 2027
Type of study
Interventional
Treatments tested
  • Gastric sleeve/bariatric surgery
Record updated
3 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a BMI of 40 - 50 kg/m2 who are having sleeve gastrectomy weight-loss surgery. Researchers will study how the body breaks down fat before and after the surgery.

Age
18 Years to 65 Years
Sex
All sexes can join.
Disease stage
BMI 40 - 50 kg/m2. No active physical illness that would interfere with mobility or weight loss after bariatric surgery.
Earlier treatment
Medications known to affect adipose tissue metabolism (for example beta blockers, corticosteroids) are not allowed.

Main reasons for not taking part

  • Type 1 or Type 2 Diabetes, or fasting plasma glucose of 126 mg/dL (7 mmol/L) or more
  • Active coronary artery disease
  • Smoking
  • Renal insufficiency (serum creatinine > 1.5mg/dl (133 µmol/L)) or chronic active liver disease
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • BMI 40 - 50 kg/m2
  • Mo active physical illness that would interfere with mobility or weight loss after bariatric surgery

Who cannot take part

  • Medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids)
  • Active coronary artery disease
  • Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose ≥126 mg/dL
  • Renal insufficiency (serum creatinine > 1.5mg/dl)
  • Chronic active liver disease (Bilirubin > 17mmol/L, AST > 144 IU/L, or ALT>165IU/L)
  • Participation in structured exercise (>2 times per week for 30 minutes or longer)
  • Smoking
  • Pregnancy or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Mayo ClinicRochester, United StatesContact: Reich PamelaTaking people

About the trial

What the trial wants to find out

It is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. Researchers will test the effects of inflammation and lipolysis regulation in people before and after bariatric surgery (sleeve gastrectomy) to answer these questions.

The group in the trial

  • Gastric sleeve surgeryTreatment being tested

    before and after weight loss from bariatric surgery

    Treatment: Gastric sleeve/bariatric surgery

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis
Plain-language title
Studies insulin control of fat breakdown before and after weight loss surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT03868592, who can take part
Record updated
3 March 2026